Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia

Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia

Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or death) according to hospital standard of care guidance) at day 15 after initiation of therapeutic intervention.

Inclusion Criteria:

• COVID19 positive
• hospitalized because of pneumonia (status #3 - #4 World Health Organization (WHO) scale)
• without contraindications to receive study treatment
• informed consent

Exclusion Criteria:

• receiving corticoids (inhaled or systemic)
• receiving anti Interleukin-1 (IL-1) or anti-IL-6 drugs
• receiving high flow oxygen therapy
• receiving mechanical ventilation
• pregnancy
• participating in another intervention trial for COVID19